AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03588039
Drug: Oraxol
RxNorm normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets
Trial: NCT01902264
Drug: EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
Trial: NCT00712699
Drug: Sequence 1: XR-MAS then placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
Trial: NCT00712699
Drug: Sequence 2 Placebo then XR-MAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
Trial: NCT00732563
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV and Orally
Trial: NCT00506662
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target, s.c. (under the skin) injection, once daily
Trial: NCT01104025
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
Trial: NCT02299167
Drug: Dixon's up-and-down method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
Trial: NCT00777101
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
Trial: NCT04267874
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02395926
Drug: Choline CR 600mg
RxNorm normalized name: choline 600 MG
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
Trial: NCT02395926
Drug: Choline CR 600mg
RxNorm normalized name: choline 600 MG
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HT-003 600mg\*2tab, administration 1 times per 1 day 8:00 a.m.
Trial: NCT01104025
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
Trial: NCT01486849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets BID for 21 days
Trial: NCT04160195
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
Trial: NCT00064337
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01452763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
Trial: NCT04330534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match BCX9930 capsules for oral administration
Trial: NCT00501397
Drug: GSK189075
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00790023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo HFA Inhaler once daily (one actuation per nostril)
Trial: NCT01452763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
Trial: NCT03009214
Drug: AMC303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
Trial: NCT00279825
Drug: CD-LD IR
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator containing 25 mg carbidopa and 100 mg levodopa
Trial: NCT00279825
Drug: IPX054 200 mg Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match IPX054 200 mg
Trial: NCT00279825
Drug: IPX054 250 mg Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match IPX054 250 mg
Trial: NCT00279825
Drug: CD-LD IR Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match CD-LD IR
Trial: NCT01549002
Drug: Intranasal Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
Trial: NCT03631732
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food
Trial: NCT03631732
Drug: NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The following NRTIs will be administered as prescribed until Week 24 without regard to food:~abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)
Trial: NCT03631732
Drug: Third Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. :~* Non-nucleoside reverse transcriptase inhibitors (NNRTIs)~  * delavirdine (DLV)~ * efavirenz (EFV)~ * nevirapine (NVP)~ * rilpivirine (RPV)~ * doravirine (DOR)~* Integrase inhibitors~  * dolutegravir (DTG)~ * elvitegravir (EVG)~ * raltegravir (RAL)~* Protease inhibitors (PIs)~  * atazanavir (ATV)~ * darunavir (DRV)~ * lopinavir (LPV)~ * nelfinavir NFV)~ * saquinavir (SQV)~ * tipranavir (TPV)~* Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)
Trial: NCT02149420
Drug: VAY736
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02149420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02832973
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg
Trial: NCT02832973
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiloride 5 mg
Trial: NCT00004259
Drug: TMZ 200mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat every 28 days for a total of 12 cycles.
Trial: NCT00004259
Drug: BCNU 150mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCNU 150 mg/m2 will be administered as an intravenous infusion on day 5 of radiotherapy, and it will be repeated every eight weeks for a total of six cycles (maximum total BCNU dose 900 mg/m2).
Trial: NCT00004259
Drug: BCNU 200mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCNU 200 mg/m2 will be administered as an intravenous infusion on day 1 of radiotherapy and will be repeated every six weeks for a total of 6 cycles (maximum BCNU dose 1200 mg/m2).
Trial: NCT00004259
Drug: TMZ 150mg/m2 six 6-week cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 6-week cycles
Trial: NCT00004259
Drug: TMZ 150mg/m2 six 8-week cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 8-week cycles
Trial: NCT03061981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
Trial: NCT00833157
Drug: glucosamine sulphate
RxNorm normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects are administered glucosamine-sulphate tablets of 500 mg \* 3 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks.
Trial: NCT00833157
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects are administered 600 mg \* 2 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks
Trial: NCT00833157
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are administered placebo tablets, while they are performing a strength-training program (\*3 weekly) with both legs for 12 weeks
Trial: NCT00223028
Drug: sirolimus, mycophenolat mofetil, fluvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01445951
Drug: Technosphere® Insulin with MedTone C Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Powder and injectable insulin
Trial: NCT01796730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01445951
Drug: Technosphere ®Insulin with Gen2 Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Powder and injectable insulin
Trial: NCT01090882
Drug: Bupivocaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20ml 0.25% at beginning of operation
Trial: NCT01090882
Drug: 0.9% normal saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20ml 0.9% NaCl
Trial: NCT00272779
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg Oral Capsules for 96 weeks
Trial: NCT01852994
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application quarterly of Testosterone Undecylate
Trial: NCT00561015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
Trial: NCT03270735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No snake venom thrombin
Trial: NCT04414800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water
Trial: NCT04414800
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1μg/kg intranasal fentanyl
Trial: NCT03440814
Drug: Placebo for DCCR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral administration
Trial: NCT04539639
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.
Trial: NCT04084197
Drug: HIP1402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (HanmiTams Capsule) 0.4mg
Trial: NCT04084197
Drug: HIP1801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4mg
Trial: NCT01437397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dose-matched placebo, twice per day
Trial: NCT01616407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules identical to MDMA or methylphenidate but containing no active drug
Trial: NCT00878423
Drug: AT13387
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
Trial: NCT00878423
Drug: AT13387
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
Trial: NCT00325728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
Trial: NCT01505569
Drug: Anti-seizure prophylaxis
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm E: Lorazepam OR Levetaracetam~* Lorazepam should be given 0.02-0.05 mg/kg/dose, given 30 minutes prior to each busulfan dose and then continuing every 6 hours, maximum dose: 2 mg.~* Levetiracetam should be given 10 mg/kg/dose PO, administered BID, staring 12 hours prior to busulfan, maximum single dose: 1000mg.
Trial: NCT01966133
Drug: Ethiodized Oil + Doxorubicin
RxNorm normalized name: ethiodized oil
DrugBank: Ethiodized oil (DB00965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE using doxorubicin-lipiodol mixture
Trial: NCT03532035
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV CDV, ganciclovir, or ribavirin.
Trial: NCT01534663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
Trial: NCT01818024
Drug: Matching placebo single dose IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo solution available for IV administration.
Trial: NCT01818024
Drug: Matching placebo single dose IH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo nebulised solution available for IH administration.
Trial: NCT01818024
Drug: Matching placebo repeat dose IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo solution available for IV administration.
Trial: NCT01818024
Drug: Matching placebo repeat dose IH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo nebulised solution available for IH administration.
Trial: NCT00005870
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00840398
Drug: BUSPAR® 30 mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 30 mg, single-dose fed
Trial: NCT01515592
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
Trial: NCT00377260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
Trial: NCT03217175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
Trial: NCT01153347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral, twice daily for 8 weeks
Trial: NCT02131194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sugar pill manufactured to mimic Lenstatin
Trial: NCT00642915
Drug: Lantus, Amaryl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01632566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally
Trial: NCT01632566
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01632566
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00385632
Drug: Antiretroviral Regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various antiretroviral therapy combinations already being administered to participants
Trial: NCT02463175
Drug: Plasmalyte
RxNorm normalized name: PLASMALYTE A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boluses of 5ml/kg of plasmalyte
Trial: NCT03154047
Drug: NEOD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: humanized monoclonal antibody
Trial: NCT00378547
Drug: paracetamol + placebo + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparing the analgesic effect of combinations of paracetamol + placebo + placebo
Trial: NCT03099187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules three times in a day.
Trial: NCT01317433
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
Trial: NCT00002601
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.
Trial: NCT04343001
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 80mg
Trial: NCT00214370
Drug: Propofol-Fentanyl
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00254462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.
Trial: NCT02292030
Drug: HTEA
RxNorm normalized name: Hydrocortisone Tetraacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: usually high thoracic epidural anesthesia
Trial: NCT01014689
Drug: Adapalene/ BPO vehicle gel with Lymecycline capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
Trial: NCT03169985
Drug: Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day
RxNorm normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.
Trial: NCT03169985
Drug: Rosuvastatin 20 mg orally once a day
RxNorm normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.
Trial: NCT00462228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
Trial: NCT01547455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
Trial: NCT00999531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Placebo, sterile saline